Tolvaptan (Jynarque)
Customize your policy alerts
Sign up for Cigna Policy IP0287 alerts
Get alerted when Policy IP0287 changes without checking for updates manually.
Monitor payer policy activity
Defines Cigna's prior authorization and medical necessity criteria for tolvaptan (Jynarque and generic) for treatment of autosomal dominant polycystic kidney disease (ADPKD) in adults; applies to Cigna-administered health benefit plans. Providers must follow the policy when requesting coverage.
The requirement regarding kidney function was updated to require a baseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2 rather than exclusion of Stage 5 CKD.
Examples of rapidly declining renal function were added, including eGFR decline ≥ 3.0 mL/min/1.73 m2 and Mayo Classification 1C, 1D, or 1E.
Policy name updated and Jynarque tablets are now available as a generic product; preferred product table for employer plans specifies trial of generic before brand under specified circumstances.
Added requirement that a patient on tolvaptan therapy cannot be on renal replacement therapy and defined renal replacement therapy as dialysis or transplantation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.